[go: up one dir, main page]

MX2012010859A - Formas polimorficas st-246 y metodos de preparacion. - Google Patents

Formas polimorficas st-246 y metodos de preparacion.

Info

Publication number
MX2012010859A
MX2012010859A MX2012010859A MX2012010859A MX2012010859A MX 2012010859 A MX2012010859 A MX 2012010859A MX 2012010859 A MX2012010859 A MX 2012010859A MX 2012010859 A MX2012010859 A MX 2012010859A MX 2012010859 A MX2012010859 A MX 2012010859A
Authority
MX
Mexico
Prior art keywords
methods
polymorphic forms
preparation
ethenocycloprop
diox
Prior art date
Application number
MX2012010859A
Other languages
English (en)
Other versions
MX361428B (es
Inventor
Dennis E Hruby
Tove C Bolken
Shanthakumar R Tyavanagimat
Melialani A C L Stone
William C Weimers
Dylan Nelson
Michael H O'neill
Gary Sweetapple
Kelley A Mccloughan
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44656766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012010859(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of MX2012010859A publication Critical patent/MX2012010859A/es
Publication of MX361428B publication Critical patent/MX361428B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • C07D209/76—4,7-Endo-alkylene-iso-indoles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se describen en la presente invención formas polimorfas de 4-trifluorometilo-N-(3, 3a, 4, 4a, 5, 5a, 6, 6a-octahidro-1,3-diox o-4,6-etenocicloprop[f]isoindol-2(1H)-ilo)-benzamida, así como sus métodos de síntesis y composiciones farmacéuticas.
MX2012010859A 2010-03-23 2011-03-23 Formas polimorficas st-246 y metodos de preparacion. MX361428B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31674710P 2010-03-23 2010-03-23
US37303110P 2010-08-12 2010-08-12
PCT/US2011/029576 WO2011119698A1 (en) 2010-03-23 2011-03-23 Polymorphic forms st-246 and methods of preparation

Publications (2)

Publication Number Publication Date
MX2012010859A true MX2012010859A (es) 2013-04-29
MX361428B MX361428B (es) 2018-12-06

Family

ID=44656766

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010859A MX361428B (es) 2010-03-23 2011-03-23 Formas polimorficas st-246 y metodos de preparacion.

Country Status (20)

Country Link
US (7) US9339466B2 (es)
EP (1) EP2549871B1 (es)
JP (3) JP6018041B2 (es)
KR (6) KR20170102070A (es)
CN (4) CN105111131A (es)
AP (1) AP3221A (es)
AU (1) AU2011232551B2 (es)
BR (1) BR112012023743B1 (es)
CA (2) CA2793533C (es)
CL (1) CL2012002621A1 (es)
DK (1) DK2549871T3 (es)
FR (1) FR22C1023I2 (es)
IL (4) IL221991B (es)
MX (1) MX361428B (es)
NZ (1) NZ602578A (es)
PE (2) PE20170944A1 (es)
RU (2) RU2015146899A (es)
SG (2) SG10201501936PA (es)
WO (1) WO2011119698A1 (es)
ZA (1) ZA201207141B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
KR20170102070A (ko) * 2010-03-23 2017-09-06 시가 테크놀로지스, 인크. 다형체 형태 ｓｔ―２４６ 및 제조방법
US9546137B2 (en) 2012-08-16 2017-01-17 Siga Technologies Inc. Methods of preparing Tecovirimat
AU2014290333B2 (en) * 2013-07-19 2018-11-08 Siga Technologies, Inc. Amorphous Tecovirimat preparation
AU2014353235B2 (en) * 2013-11-19 2019-05-09 Siga Technologies, Inc. Rehydration of micronized tecovirimat monohydrate
CA2962597A1 (en) * 2014-09-26 2016-03-31 Millendo Therapeutics, Inc. Solid drug form of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
CN108430469A (zh) 2016-02-16 2018-08-21 西加技术公司 St-246(特考韦瑞一水合物)混悬制剂
US11677080B2 (en) 2017-03-31 2023-06-13 Osaka Gas Co., Ltd. Electrochemical element, electrochemical module, solid oxide fuel cell and manufacturing method
RU2716709C1 (ru) * 2019-08-20 2020-03-16 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Пероральная лекарственная форма препарата в капсулах для лечения и профилактики заболеваний, вызываемых ортопоксвирусами
JP2024178478A (ja) * 2021-11-04 2024-12-25 興和株式会社 医薬品
JP2024178477A (ja) * 2021-11-04 2024-12-25 興和株式会社 カプセル剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670901A1 (de) 1967-08-09 1971-03-18 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US4173646A (en) 1974-10-04 1979-11-06 Merck & Co., Inc. Tricyclicdicarboximides
US4061763A (en) 1975-05-09 1977-12-06 Merck & Co., Inc. Tricyclicdicarboximides
US5068356A (en) 1990-02-20 1991-11-26 Atochem North America, Inc. Hindered phenolic n-(amido)imides
ZA939565B (en) 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP4334869B2 (ja) 2000-12-01 2009-09-30 協和発酵キリン株式会社 溶解性または経口吸収性の改善された組成物
US6596771B2 (en) 2001-01-12 2003-07-22 Schering Corporation Drugs for treating viral infections
US6433016B1 (en) 2001-01-12 2002-08-13 Vassil Stefanov Georgiev Drugs for treating viral infections
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US7737168B2 (en) 2003-06-20 2010-06-15 Siga Technologies, Inc. Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US7687641B2 (en) * 2003-06-20 2010-03-30 Siga Technologies, Inc. Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
CA2529761C (en) * 2003-06-20 2013-08-13 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US8530509B2 (en) 2003-06-20 2013-09-10 Siga Technologies, Inc. Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
US20070122471A1 (en) 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
US20090005429A1 (en) * 2004-12-09 2009-01-01 Zach System S.P.A. Process for the preparation of carvedilol and its enantiomers
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP1988776B1 (en) 2006-03-02 2012-08-08 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CN104758281A (zh) 2007-04-23 2015-07-08 西佳技术公司 用于治疗和预防正痘病毒感染和相关疾病的化合物、组合物和方法
CN101445478B (zh) * 2008-08-22 2011-04-06 中国人民解放军军事医学科学院生物工程研究所 含一个结晶水的化合物st-246及其晶体与制备方法
RU2412160C1 (ru) * 2009-09-25 2011-02-20 Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФГУН ГНЦ ВБ "Вектор" Роспотребнадзора) 7-[n'-(4-трифторметилбензоил)-гидразинокарбонил]-трицикло[3.2.2.02,4]нон-8-ен-6-карбоновая кислота, обладающая противовирусной активностью
KR20170102070A (ko) * 2010-03-23 2017-09-06 시가 테크놀로지스, 인크. 다형체 형태 ｓｔ―２４６ 및 제조방법

Also Published As

Publication number Publication date
WO2011119698A1 (en) 2011-09-29
KR20130018271A (ko) 2013-02-20
IL241730A0 (en) 2015-11-30
US20110236434A1 (en) 2011-09-29
MX361428B (es) 2018-12-06
SG184201A1 (en) 2012-10-30
AP3221A (en) 2015-04-30
RU2015146899A (ru) 2019-01-11
PE20130212A1 (es) 2013-03-09
KR20150092354A (ko) 2015-08-12
WO2011119698A9 (en) 2013-01-31
US10406137B2 (en) 2019-09-10
CA2793533A1 (en) 2011-09-29
US20210137885A1 (en) 2021-05-13
KR20160062208A (ko) 2016-06-01
US20180311213A1 (en) 2018-11-01
BR112012023743A2 (pt) 2015-09-15
US20180193308A1 (en) 2018-07-12
EP2549871A1 (en) 2013-01-30
IL258239A (en) 2018-05-31
CN105175311A (zh) 2015-12-23
US11890270B2 (en) 2024-02-06
JP6018041B2 (ja) 2016-11-02
JP2013522371A (ja) 2013-06-13
IL241731A0 (en) 2015-11-30
NZ602578A (en) 2014-08-29
FR22C1023I1 (fr) 2022-07-22
CL2012002621A1 (es) 2013-10-11
PE20170944A1 (es) 2017-07-13
CA3030671A1 (en) 2011-09-29
KR20170102070A (ko) 2017-09-06
RU2578606C2 (ru) 2016-03-27
DK2549871T3 (en) 2018-12-10
IL221991B (en) 2019-06-30
CA2793533C (en) 2019-02-26
AU2011232551A1 (en) 2012-10-18
US10933050B2 (en) 2021-03-02
CN105111130A (zh) 2015-12-02
FR22C1023I2 (fr) 2024-02-16
JP2018012735A (ja) 2018-01-25
US20240156782A1 (en) 2024-05-16
US9339466B2 (en) 2016-05-17
ZA201207141B (en) 2016-06-29
KR20160028489A (ko) 2016-03-11
CN103068232B (zh) 2015-08-26
SG10201501936PA (en) 2015-05-28
US12433868B2 (en) 2025-10-07
US20160107993A1 (en) 2016-04-21
CN105111131A (zh) 2015-12-02
RU2012144818A (ru) 2014-04-27
EP2549871A4 (en) 2016-03-09
AU2011232551B2 (en) 2014-11-13
US9744154B2 (en) 2017-08-29
US10045964B2 (en) 2018-08-14
CN103068232A (zh) 2013-04-24
BR112012023743B1 (pt) 2020-02-18
AP2012006514A0 (en) 2012-10-31
KR20150011016A (ko) 2015-01-29
EP2549871B1 (en) 2018-08-22
JP2016040323A (ja) 2016-03-24
US20190343799A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
MX2012010859A (es) Formas polimorficas st-246 y metodos de preparacion.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
PH12013500500A1 (en) Fused heteroaryls and their uses
MX2016008448A (es) Conjugados de var2csa-farmaco.
NZ603151A (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
AU321832S (en) Neck support
MY173526A (en) Novel anti-?5?1 antibodies and uses thereof
UY34185A (es) ?partículas cristalinas recubiertas con micelas de copolímeros, composiciones, proceso de preparación de dichas partículas y sus usos?.
AU323858S (en) Support
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
GB201214580D0 (en) Benzocyanine compounds
ECSP12011653A (es) Derivados de n1-acil-5-fluoropirimidinona
MY161868A (en) Anti-bv8 antibodies and uses thereof
AU318469S (en) Cosmetic container
AU319429S (en) Pen
IN2012DN03404A (es)
IN2014KN02722A (es)
EA201270377A1 (ru) Стабильные композиции sns-595 и способы их получения
IN2015DN04074A (es)
AU2011298391A8 (en) Substituted N-phenethyltriazoloneacetamides and uses thereof
EP3456837A3 (en) Decorin compositions and use thereof
AU2013338098A8 (en) Solid salt form of alpha-6-mPEG6-O-hydroxycodone as opioid agonists and uses thereof
MX2013003859A (es) Polimorfos de picropodofilina b o c para su uso en la terapia del cancer.
CL2008001819A1 (es) Compuestos derivados de fenoxi-fluorobenceno sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades virales tales como vih y sida.

Legal Events

Date Code Title Description
FG Grant or registration